Neurocrine Biosciences (BSP:N1BI34) EPS (Basic) : R$0.95 (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Neurocrine Biosciences EPS (Basic)?

Neurocrine Biosciences's basic earnings per share (Basic EPS) for the three months ended in Dec. 2024 was R$0.31. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was R$0.95.

Neurocrine Biosciences's EPS (Diluted) for the three months ended in Dec. 2024 was R$0.31. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was R$0.92.

Neurocrine Biosciences's EPS without NRI for the three months ended in Dec. 2024 was R$0.52. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was 1.26.

During the past 12 months, Neurocrine Biosciences's average EPS without NRIGrowth Rate was 64.00% per year. During the past 3 years, the average EPS without NRI Growth Rate was 49.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 12.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Neurocrine Biosciences's highest 3-Year average EPS without NRI Growth Rate was 157.70% per year. The lowest was -58.60% per year. And the median was -2.10% per year.

Neurocrine Biosciences EPS (Basic) Historical Data

The historical data trend for Neurocrine Biosciences's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences EPS (Basic) Chart

Neurocrine Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

Get a 7-Day Free Trial

1.13

0.27

0.42

0.63

1.04

Neurocrine Biosciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EPS (Basic)	Get a 7-Day Free Trial															0.37	0.11	0.17	0.35	0.31

Neurocrine Biosciences EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Neurocrine Biosciences's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(2082.271	-	0)	/	2008.000
	=	1.04

Neurocrine Biosciences's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(629.013	-	0)	/	1996.000
	=	0.32

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$0.95

Neurocrine Biosciences (BSP:N1BI34) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Neurocrine Biosciences EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurocrine Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (BSP:N1BI34) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

NBIX:USA 0K6R:UK NB3:Germany

Address

6027 Edgewood Bend Court, San Diego, CA, USA, 92130

Website

https://www.neurocrine.com

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Neurocrine Biosciences Headlines

No Headlines